New NIH Small Business Innovation Research Award Received by Dr. Sara Jane Ward and Lewis Katz School of Medicine Scientists for Further Exploration of CBD Analog’s Therapeutic Potential

Thanks to a new Phase 2 Small Business Innovation Research (SBIR) award from the National Institutes of Health, scientists at the Lewis Katz School of Medicine at Temple University will have the opportunity to further explore the therapeutic potential of a CBD analog known as KLS-13019. The Phase 2 SBIR is a collaboration between Temple University and Kannalife Sciences, a subsidiary of Neuropathix, Inc., which developed and patented KLS-13019. Sara Jane Ward, PhD, Assistant Professor of Neural Sciences and Assistant Professor in the Center for Substance Abuse Research at the Katz School of Medicine, is a co-principal investigator on the grant. News-Medical.net highlighted the news.